CN109310622A - 尼古丁颗粒和组合物 - Google Patents

尼古丁颗粒和组合物 Download PDF

Info

Publication number
CN109310622A
CN109310622A CN201780034796.4A CN201780034796A CN109310622A CN 109310622 A CN109310622 A CN 109310622A CN 201780034796 A CN201780034796 A CN 201780034796A CN 109310622 A CN109310622 A CN 109310622A
Authority
CN
China
Prior art keywords
nicotine
particle
acid
sugar
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780034796.4A
Other languages
English (en)
Chinese (zh)
Inventor
G·聚贝
N·沃尔普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philip Morris Products SA
Original Assignee
Philip Morris Products SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products SA filed Critical Philip Morris Products SA
Publication of CN109310622A publication Critical patent/CN109310622A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
CN201780034796.4A 2016-06-30 2017-06-14 尼古丁颗粒和组合物 Pending CN109310622A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16177163.9 2016-06-30
EP16177163 2016-06-30
PCT/IB2017/053543 WO2018002756A1 (en) 2016-06-30 2017-06-14 Nicotine particles and compositions

Publications (1)

Publication Number Publication Date
CN109310622A true CN109310622A (zh) 2019-02-05

Family

ID=56296661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034796.4A Pending CN109310622A (zh) 2016-06-30 2017-06-14 尼古丁颗粒和组合物

Country Status (19)

Country Link
US (2) US20190133940A1 (https=)
EP (1) EP3478264B1 (https=)
JP (2) JP2019524648A (https=)
KR (1) KR102523677B1 (https=)
CN (1) CN109310622A (https=)
AR (1) AR108920A1 (https=)
AU (1) AU2017286864A1 (https=)
CA (1) CA3023630A1 (https=)
ES (1) ES3055891T3 (https=)
IL (1) IL263355A (https=)
MX (1) MX385972B (https=)
PH (1) PH12018502714A1 (https=)
PL (1) PL3478264T3 (https=)
RU (1) RU2767064C2 (https=)
SG (1) SG11201809594WA (https=)
TW (1) TW201801716A (https=)
UA (1) UA124535C2 (https=)
WO (1) WO2018002756A1 (https=)
ZA (1) ZA201806949B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114828825A (zh) * 2019-08-30 2022-07-29 塔克索公司 装载的颗粒、其生产方法及其用途
CN115135175A (zh) * 2019-12-19 2022-09-30 尤尔实验室有限公司 有机基尼古丁凝胶组合物
US12369617B2 (en) 2019-12-19 2025-07-29 Juul Labs, Inc. Metal oxide-based gel nicotine compositions
US12612312B2 (en) 2019-12-20 2026-04-28 Juul Labs, Inc. Hydrated ionic clay and tobacco material compositions

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3055891T3 (en) * 2016-06-30 2026-02-16 Philip Morris Products Sa Nicotine particles and compositions
WO2020071448A1 (ja) * 2018-10-02 2020-04-09 学校法人名城大学 吸入粉末剤、その評価方法及びその用途
CN110384700A (zh) * 2019-09-03 2019-10-29 云南喜科科技有限公司 一种合成尼古丁的组合物
UA130281C2 (uk) 2019-11-14 2026-01-07 Філіп Морріс Продактс С.А. Сухий порошковий склад зі смаком тютюну, спосіб його одержання та порошкова система
WO2021201258A1 (ja) * 2020-04-01 2021-10-07 株式会社ＳｔａｔｅＡｒｔ 核酸含有組成物、核酸含有組成物の製造方法及び核酸導入方法
ES3040112T3 (en) * 2020-06-15 2025-10-28 Philip Morris Products Sa Anatabine powder compositions
BR112023003114A2 (pt) * 2020-09-03 2023-04-04 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade liofilizadas
WO2022049488A1 (en) * 2020-09-03 2022-03-10 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
US12594238B2 (en) * 2020-09-03 2026-04-07 Philip Morris Products S.A. Low hygroscopicity active powder compositions
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
CN1384733A (zh) * 1999-10-29 2002-12-11 吸入治疗系统公司 分散性得到改进的干粉组合物
JP2003519175A (ja) * 1999-12-30 2003-06-17 カイロン コーポレイション インターロイキン−２の肺送達のための方法
JP2004515467A (ja) * 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
US20040118007A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20060084656A1 (en) * 2004-10-15 2006-04-20 Pfizer Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
US20080226736A1 (en) * 2005-10-21 2008-09-18 Eratech S.R.L. Inhalatory Pharmaceutical Compositions in Form of Dry Powders, Solutions or Suspensions Obtained From the Same and Process for their Preparation
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20150283070A1 (en) * 2014-04-08 2015-10-08 Sansa Corporation (Barbados) Inc. Nicotine Formulations and Methods of Making the Same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
FI20060428A7 (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
CA2943746C (en) * 2014-04-28 2023-08-15 Philip Morris Products S.A. Flavoured nicotine powder inhaler
US10149844B2 (en) * 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
ES3055891T3 (en) * 2016-06-30 2026-02-16 Philip Morris Products Sa Nicotine particles and compositions
PL3478265T3 (pl) * 2016-06-30 2025-04-14 Philip Morris Products S.A. Cząstki nikotyny
IL269275B2 (en) * 2017-06-28 2023-04-01 Philip Morris Products Sa Container with particles for use with an inhaler

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013893A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
CN1384733A (zh) * 1999-10-29 2002-12-11 吸入治疗系统公司 分散性得到改进的干粉组合物
JP2003519175A (ja) * 1999-12-30 2003-06-17 カイロン コーポレイション インターロイキン−２の肺送達のための方法
JP2004515467A (ja) * 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
US20040118007A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20060084656A1 (en) * 2004-10-15 2006-04-20 Pfizer Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
US20080226736A1 (en) * 2005-10-21 2008-09-18 Eratech S.R.L. Inhalatory Pharmaceutical Compositions in Form of Dry Powders, Solutions or Suspensions Obtained From the Same and Process for their Preparation
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20150283070A1 (en) * 2014-04-08 2015-10-08 Sansa Corporation (Barbados) Inc. Nicotine Formulations and Methods of Making the Same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROKO OTAKE ET AL.: "Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device", 《PHARM. RES.》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114828825A (zh) * 2019-08-30 2022-07-29 塔克索公司 装载的颗粒、其生产方法及其用途
CN115135175A (zh) * 2019-12-19 2022-09-30 尤尔实验室有限公司 有机基尼古丁凝胶组合物
US12369617B2 (en) 2019-12-19 2025-07-29 Juul Labs, Inc. Metal oxide-based gel nicotine compositions
US12389934B2 (en) 2019-12-19 2025-08-19 Juul Labs, Inc. Organic-based nicotine gel compositions
US12612312B2 (en) 2019-12-20 2026-04-28 Juul Labs, Inc. Hydrated ionic clay and tobacco material compositions

Also Published As

Publication number Publication date
AU2017286864A1 (en) 2018-11-15
IL263355A (en) 2018-12-31
ZA201806949B (en) 2019-07-31
JP2019524648A (ja) 2019-09-05
AR108920A1 (es) 2018-10-10
MX385972B (es) 2025-03-18
RU2018145313A (ru) 2020-07-30
EP3478264C0 (en) 2025-11-19
CA3023630A1 (en) 2018-01-04
MX2018015118A (es) 2019-04-15
RU2767064C2 (ru) 2022-03-16
EP3478264A1 (en) 2019-05-08
RU2021132299A (ru) 2021-12-10
ES3055891T3 (en) 2026-02-16
SG11201809594WA (en) 2018-11-29
TW201801716A (zh) 2018-01-16
KR102523677B1 (ko) 2023-04-20
US20210361567A1 (en) 2021-11-25
PH12018502714A1 (en) 2019-07-29
PL3478264T3 (pl) 2026-02-02
UA124535C2 (uk) 2021-10-05
JP2022071106A (ja) 2022-05-13
WO2018002756A1 (en) 2018-01-04
EP3478264B1 (en) 2025-11-19
US20190133940A1 (en) 2019-05-09
KR20190025824A (ko) 2019-03-12
RU2018145313A3 (https=) 2020-07-30
BR112018076215A2 (pt) 2019-03-26

Similar Documents

Publication Publication Date Title
CN109310622A (zh) 尼古丁颗粒和组合物
JP7471774B2 (ja) ニコチン粒子
Chang et al. Advancements in particle engineering for inhalation delivery of small molecules and biotherapeutics
JP2016034951A (ja) ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
Q. Li, JH Hu, B. Lu, H. Yao, WG Zhang Ciprofloxacin-loaded bovine serum albumin microspheres: preparation and drug-release in vitro
ES2339423T3 (es) Composiciones terapeuticas para administracion pulmonar.
WO2003070023A1 (en) Amino acid powder and process for producing the same
JP2013082660A (ja) ニコチン薬の製造法およびその方法により製造される医薬
CN113750052B (zh) 一种乙酰半胱氨酸颗粒及其制备方法
JP2008500411A5 (https=)
RU2847582C2 (ru) Никотиносодержащие частицы и композиции
JP2023521150A5 (https=)
BR112018076215B1 (pt) Partículas compreendendo sal de nicotina, composições compreendendo as mesmas e método de preparação
US20250041214A1 (en) Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
NZ747471A (en) Nicotine particles and compositions
CN119925312A (zh) 干粉吸入式的医药组合物及其制备方法
KR20180052566A (ko) 폐 전달용 트립탄 분말
KR20100032116A (ko) 아세트아미노펜의 호흡식 치료용 분말 및 이의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination